Xuefu-Zhuyu Capsule for the Treatment of "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome)

Exclusion Criteria

• •Patients with acute myocardial infarction, rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia and other severe arrhythmias and severe cardiac and pulmonary insufficiency in the past 3 months
• •Patients with acute cerebrovascular disease such as cerebral infarction and cerebral hemorrhage in the past 3 months;
• •Those with poorly controlled hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg after treatment);
• •Patients with aortic dissection;
• •Patients with abnormal liver and kidney function indicators (ALT, AST are 1.5 times greater than the upper limit of normal value, and Scr is greater than the upper limit of normal value);
• •SAS≥70 points;
• •SDS≥73 points;
• •VAS≥80 points;
• •Patients with severe primary heart, brain, liver, kidney, and hematopoietic diseases;
• •Women during pregnancy and lactation;
• •Those with cognitive impairment, consciousness impairment or mental illness, who cannot communicate normally;
• •People with allergies, or those who are known to be allergic to the trial drug (including its components);
• •Surgery(including intervention, radio frequency, etc.) during the past 4 weeks;
• •Those with bleeding tendency;
• •Those who suspect or have a history of alcohol or drug abuse;
• •Participation in another trial in the past 1 month;
• •Other circumstances judged by the researcher to be unsuitable for participation in the trial.